RESEARCH Open Access



# Synergistic association between underweight and type 2 diabetes on the development of laryngeal cancer: a national population-based retrospective cohort study

Oh. Hyeong Lee<sup>1</sup>, Yong-Moon Park<sup>2</sup>, Seung-Hyun Ko<sup>3</sup>, Kyuna Lee<sup>4</sup>, Yeonji Kim<sup>1</sup>, Kyungdo Han<sup>5\*</sup> and Jung-Hae Cho<sup>1\*</sup>

#### **Abstract**

**Background:** Although cigarette smoking is the most significant risk factor for laryngeal cancer, other risk factors might also be associated with the development of laryngeal cancer. We investigated whether underweight and type 2 diabetes are associated with laryngeal cancer in a Korean population.

**Methods:** A total of 9,957,059 participants (≥20 years) without prior history of cancer who underwent a National Health Insurance Service health checkup in 2009 were followed up until December 31, 2018. Newly diagnosed laryngeal cancer was identified using claim data, and underweight was defined as body mass index (BMI) < 18.5 kg/m². A Cox proportional-hazards models with multivariable adjustment were used to estimate hazard ratios (HRs) and corresponding 95% confidence intervals (95% Cls).

**Results:** During the median follow-up period of 8.3 years, 3504 cases of laryngeal cancer occurred. Underweight was associated with increased risk of laryngeal cancer after adjusting for potential confounders (HR: 1.43, 95% Cl: 1.22– 1.69) compared to those who were not underweight. Underweight and type 2 diabetes were synergistically associated with higher risk of laryngeal cancer (HR: 2.33, 95% Cl: 1.54–3.51), compared to those without either condition. This relationship was stronger in those with an age < 65 years (HR: 3.33, 95% Cl: 1.88–5.87) and alcohol consumption (HR: 2.72, 95% Cl: 1.64–4.53).

**Conclusions:** These results suggest that underweight may be a significant risk factor for laryngeal cancer and that underweight and type 2 diabetes might synergistically increase the risk of laryngeal cancer.

Keywords: Laryngeal cancer, Body mass index, Underweight, Type 2 diabetes, Diabetes mellitus, Cohort, Risk factors

Full list of author information is available at the end of the article

# **Background**

Over the past 20 years, the smoking rate among men decreased by half from 66.3% in 1998 to 36.7% in 2018 due to the influence of a national anti-smoking campaign in Korea [1]. On the other hand, the female smoking rate slightly increased from 6.5% in 1998 to 7.5% in 2018. Smoking is the single greatest risk factor for head and



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and you rintended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativeccommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeccommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

<sup>\*</sup>Correspondence: hkd917@naver.com; jhchomd@catholic.ac.kr

<sup>&</sup>lt;sup>1</sup> Department of Otolaryngology-Head and Neck Surgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon-si, Republic of Korea

Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea

Lee et al. BMC Cancer (2022) 22:345 Page 2 of 10

neck cancer (HNC), especially laryngeal cancer. Annually, over 184,000 people are newly diagnosed with laryngeal cancer, which is the 2nd most common cancer of the head and neck worldwide [2]. More than 1000 patients were newly diagnosed with laryngeal cancer in Korea in 2020 [3]. Although the smoking population is continuously decreasing, the global incidence of laryngeal cancer is not decreasing [4]. This trend suggests that there may be other potential risk factors for laryngeal cancer.

According to changes in lifestyle and dietary habits, and steady increases in the rates of chronic metabolic diseases such as obesity and diabetes mellitus (DM) during the last several decades, some metabolic parameters have been suggested as risk factors for the development of cancers [5, 6]. In general, DM and obesity are important contributing factors for solid organ cancers, including liver, kidney, colorectal, and pancreatic cancers [7–10].

It has been documented that body mass index (BMI) is inversely associated with the development of oral cancer, lung cancer, and esophageal squamous cell carcinoma, which are all closely related to tobacco smoking [11, 12]. Previous studies have found that people with a BMI <18.5 kg/m² experience a higher risk of HNC than people with a normal BMI (18.5–25.0 kg/m²) [12–15]. According to studies reporting an inverse relationship between BMI and HNC risk, similar results were confirmed in only a small number of patients with laryngeal cancer in populations from China and the Netherlands with short follow-up periods [13, 16].

DM is also known to be associated with the development of HNC, especially oral and nasopharyngeal cancer [17, 18]. In Korea, approximately half of patients with DM (53.2%) are obese [19], and cancer risk increases in patients with DM, especially in obese subjects [7]. However, this association has not yet been confirmed in individuals with HNC.

In this Korean nationwide population-based study, we aimed to investigate the association between BMI and laryngeal cancer risk and whether this association is mediated by type 2 diabetes.

#### Methods

#### Data source and study population

In this retrospective cohort study, we used the Korean National Health Insurance System (NHIS) database, which is government managed and the only insurer providing regular health check-up programs to the public in South Korea. Based on the law, the NHIS may perform compulsory financial collections from the insured. The data collected for this operation is called 'qualification and contribution data'. Those enrolled in the health insurance service are recommended to undergo

health check-ups at least biennially. In the present study, we included 10,585,852 subjects aged >20 years who underwent a health examination in 2009. Participants who were diagnosed with larvngeal cancer during the preceding year or within 1 year after enrollment were excluded. Of these subjects, we excluded 164,158 having prior malignancy and 370,388 with missing data (Fig. 1). This study was conducted according to the Declaration of Helsinki and approved by the Institutional Review Board of the Catholic University of Korea (IRB No. VC21ZISI0191). Because anonymized and deidentified information was used in the analyses, the requirement for informed consent was waived by the Institutional Review Board of the Catholic University of Korea (IRB No. VC21ZISI0191). The reporting of this study followed recommendations in the Reporting Studies Conducted using Observational Routinely collected health Data (RECORD) guidelines [20].


# Definition of laryngeal cancer

The primary outcome was newly diagnosed laryngeal cancer during the follow-up period. The diagnosis of laryngeal cancer was detected by surveillance of the disease code. Laryngeal cancers were coded as International Classification of Diseases (ICD-10) codes such as C101, C320, C321, C322, C323, C328 and C329. Because the Korean Health Insurance Review and Assessment Service reimburses all medical care expenses for confirmed cancer, all cancer patients are registered in the database. Therefore, we could include each newly diagnosed cancer patient in the whole South Korean population. The study population was followed from baseline at the index year to the date of cancer diagnosis, December 31, 2018, or death, whichever came first.

# **Data collection**

Standardized self-reported questionnaires were used to collect baseline data for the following variables: age (years), sex, cigarette smoking (never, ex and current), alcohol consumption (never, mild and heavy), and physical activity. Smoking status was divided into three groups: nonsmoker (less than 5 packs or 100 cigarettes in lifetime), ex-smoker (smoked more than 5 packs or 100 cigarettes in life but not currently smoking), and current smoker (smoked more than 5 packs or 100 cigarettes in life and still smoking) [21]. Alcohol consumption was categorized into none, mild (<30 g/day ethanol) and heavy (>30 g/day ethanol).

Regular physical activities were evaluated according to the weekly frequency of moderate- or vigorous-intensity physical activity. Income status was divided into four groups based on health insurance contributions: Q1 (the lowest quartile), Q2, Q3 and Q4 (the highest quartile). Lee et al. BMC Cancer (2022) 22:345 Page 3 of 10



BMI was calculated as weight in kilograms divided by height in square meters. BMI was categorized into five groups; underweight (<18.5 kg/m<sup>2</sup>), normal weight  $(18.5-22.9 \text{ kg/m}^2)$ , overweight  $(23-24.9 \text{ kg/m}^2)$ , obese  $(25-30 \text{ kg/m}^2)$ , and severely obese  $(\geq 30 \text{ kg/m}^2)$  according to World Health Organization (WHO) guidelines for the Asian-Pacific region [22]. Blood samples for the measurement of serum glucose, total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol levels were drawn after fasting overnight. The presence of type 2 diabetes was defined according to the following criteria: (1) at least one claim per year under ICD-10 codes E11-14 and at least one claim per year for antidiabetic drug prescription or (2) fasting glucose level  $\geq 126 \,\mathrm{mg/dL}$  [23]. Patients with type 1 diabetes who had claims under ICD-10 code E10 were excluded from this study. Hypertension was defined based on ICD-10 codes I10-I13 and I15 plus a history of antihypertensive drug prescription. Dyslipidemia was defined as a total cholesterol level  $\geq$  6.21 mmol/L ( $\geq$ 240 mg/dL) or the presence of one or more claims per year for antihyperlipidemic medications with ICD-10 code E78. Patients with an estimated glomerular filtration rate (eGFR) < 60 mL/ min/1.73 m<sup>2</sup> at the time of baseline evaluation were classified as having chronic kidney disease (CKD) using the Modification of Diet in Renal Disease (MDRD) equation [24]. Anemia was defined in accordance with the WHO

criteria as hemoglobin < 13 g/dL in men and < 12 g/dL in women [25].

#### Statistical analysis

Data are presented as the mean  $\pm$  standard deviation, median value (interquartile range) or n (%). The incidence of primary outcomes was calculated by dividing the number of incident cases by the total follow-up duration (person-years). The  $\chi^2$  test was used to determine differences in the proportions of categorical variables, and Student's t test was used to evaluate differences between the means of continuous variables. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the development of laryngeal cancer were calculated using a Cox proportional hazards model for the association of BMI and type 2 diabetes after adjusting for confounders. The P values provided are two-sided, with the level of significance at 0.05.

A multivariable-adjusted proportional-hazards model was applied. Model 1 was adjusted for age, sex. Model 2 was adjusted further for income status, smoking, alcohol consumption, and physical activity. We further adjusted for type 2 diabetes, hypertension, dyslipidemia, and anemia in model 3. Subgroup analyses were performed to determine whether the association between laryngeal cancer and underweight with type 2 diabetes varies according to participant characteristics. Statistical analyses were performed using SAS software (v. 9.4; SAS Institute) and a p value < 0.05 was considered significant.

Lee et al. BMC Cancer (2022) 22:345 Page 4 of 10

# **Results**

During the mean follow-up duration of  $8.2\pm0.9\,\mathrm{years}$ , there were 3504 individuals with newly diagnosed laryngeal cancer among 9,957,059 participants (Fig. 1). Table 1 shows the baseline characteristics of participants

according to the development of laryngeal cancer. Compared with the individuals without laryngeal cancer, those with laryngeal cancer were more likely to be male, older, lean, abdominal obesity, current smokers, and alcohol consumers and to have type 2 diabetes, hypertension,

 Table 1
 Baseline characteristics of the study population according to the development of laryngeal cancer

Parameter	Laryngeal cancer $(-)$	Laryngeal cancer (+)	<i>p</i> -value
	(n=9,953,555)	(n=3504)	
Age at enrollment, years			
Mean	$46.83 \pm 14$	61.63 ± 9.94	<.0001
Categories, n (%)			<.0001
20–39	3,196,973 (32.12)	60 (1.71)	
40–64	5,503,198 (55.29)	2011 (57.39)	
≥65	1,253,384 (12.59)	1433 (40.9)	
Male, n (%)	5,494,878 (55.2)	3322 (94.8)	<.0001
Smoking, n (%)			<.0001
Nonsmoker	5,889,510 (59.17)	812 (23.17)	
Ex-smoker	1,422,335 (14.29)	863 (24.63)	
Current smoker	2,641,710 (26.54)	1829 (52.2)	
Alcohol consumption, n (%)			<.0001
Nondrinker	5,078,363 (51.02)	1298 (37.04)	
Mild drinker	4,075,549 (40.95)	1518 (43.32)	
Heavy drinker	799,643 (8.03)	688 (19.63)	
Regular physical activity, n (%)	1,795,502 (18.0)	782 (22.3)	<.0001
Low income (Q1), n (%)	2,133,192 (21.43)	766 (21.86)	0.54
Type 2 diabetes, n (%)	855,037 (8.59)	659 (18.81)	<.0001
Anemia, <i>n</i> (%)	1,072,898 (10.78)	422 (12.04)	0.02
Hemoglobin, g/dL	13.97 ± 1.6	$14.38 \pm 1.42$	<.0001
Hypertension, n (%)	2,537,201 (25.49)	1687 (48.14)	<.0001
Dyslipidemia, n (%)	1,791,225 (18)	824 (23.52)	<.0001
Chronic kidney disease, n (%)	677,243 (6.8)	341 (9.73)	<.0001
Height, cm	163.99±9.27	$166.01 \pm 6.52$	<.0001
Weight, kg	$64.03 \pm 11.67$	64.59 ± 10.15	0.01
BMI, kg/m <sup>2</sup>			
Mean	$23.71 \pm 3.45$	$23.38 \pm 3.04$	<.0001
Categories, n (%)			<.0001
< 18.5	365,663 (3.67)	155 (4.42)	
18.5–22.9	3,872,796 (38.91)	1429 (40.78)	
23–24.9	2,454,246 (24.66)	912 (26.03)	
25–29.9	2,905,612 (29.19)	932 (26.6)	
≥30	355,238 (3.57)	76 (2.17)	
Waist circumference, cm	$80.24 \pm 9.46$	$83.9 \pm 8.14$	<.0001
Fasting glucose, mg/dL	$97.17 \pm 23.8$	$104.19 \pm 28.25$	<.0001
Systolic blood pressure, mm Hg	$122.4 \pm 15.02$	$128.5 \pm 16$	<.0001
Diastolic blood pressure, mm Hg	$76.3 \pm 10.05$	$78.8 \pm 10.08$	<.0001
Total cholesterol, mg/dL	195.32±41.39	194.06 ± 49.4	0.07
HDL cholesterol, mg/dL	56.5 ± 32.96	$55.96 \pm 41.93$	0.33
LDL cholesterol, mg/dL	$121.35 \pm 216.89$	111.58±63.37	0.01

Data are mean SD or n (%)

Lee et al. BMC Cancer (2022) 22:345 Page 5 of 10

anemia, dyslipidemia, and higher fasting glucose. Income level or socioeconomic status was not different between the two groups.

Table 2 shows the association between BMI and laryngeal according to adjusted regression models. The incidence rate (IR) of laryngeal cancer was highest in underweight (0.052 events per 1000 person-years). In fully adjusted Cox regression models adjusted for age, sex, income level, smoking, alcohol consumption, regular

physical activity, type 2 diabetes, hypertension, dyslipidemia and anemia, underweight (BMI <  $18.5 \,\mathrm{kg/m^2}$ ) was significantly associated with increased risk of laryngeal cancer, compared to those with a BMI  $\geq 18.5 \,\mathrm{kg/m^2}$  (HR: 1.43, 95% CI: 1.22–1.69), and those with a BMI  $18.5-22.9 \,\mathrm{kg/m^2}$  (HR: 1.25, 95% CI: 1.06–1.48), respectively.

The interaction between underweight and type 2 diabetes in the association with the risk of laryngeal cancer was shown in Fig. 2. Underweight and type 2


**Table 2** Hazard ratios for developing laryngeal cancer according to BMI

	IR (per 1000 person-years)	HR (95% CI)		
		Model 1	Model 2	Model 3
Underweight				
< 18.5	0.052	1.59 (1.35-1.87)	1.36 (1.16–1.60)	1.43 (1.22-1.69)
≥ 18.5	0.042	1 (Reference)	1 (Reference)	1 (Reference)
BMI, kg/m <sup>2</sup>				
< 18.5	0.052	1.35 (1.14–1.59)	1.23 (1.04–1.45)	1.25 (1.06-1.48)
18.5-22.9	0.045	1 (Reference)	1 (Reference)	1 (Reference)
23-24.9	0.045	0.81 (0.74-0.88)	0.87 (0.80-0.94)	0.84 (0.78-0.92)
25-29.9	0.039	0.71 (0.65-0.77)	0.78 (0.72-0.85)	0.74 (0.68-0.81)
≥30	0.026	0.77 (0.61-0.96)	0.83 (0.66-1.05)	0.76 (0.60-0.96)

Model 1 was adjusted for age, sex

Model 2 was adjusted for age, sex, income status, smoking, alcohol consumption, and physical activity

Model 3 was adjusted for age, sex, income status, smoking, alcohol consumption, physical activity, type 2 diabetes, hypertension, dyslipidemia, and anemia *Abbreviations: BMI* Body mass index, *CI* Confidence interval, *HR* Hazard ratio, *IR* Incidence rate (1000 person-year)



**Fig. 2** Association between underweight, type 2 diabetes and the development of laryngeal cancer. The combination of underweight and type 2 diabetes showed a higher risk of laryngeal cancer. The analysis was adjusted for age, sex, smoking, alcohol consumption, regular physical activity, income, type 2 diabetes, hypertension, dyslipidemia, chronic kidney disease, and anemia

Lee et al. BMC Cancer (2022) 22:345 Page 6 of 10

diabetes were synergistically associated with increased risk of laryngeal cancer. Individual with both underweight and type 2 diabetes showed the highest risk of laryngeal cancer (HR: 2.33, 95% CI: 1.54–3.51). The association between BMI and the risk of laryngeal cancer according to type 2 diabetes status was shown in Table 3. Compared to those who had a normal weight (BMI  $18.5-22.9\,\mathrm{kg/m^2}$ ) but had no type 2 diabetes, those with a BMI <  $18.5\,\mathrm{kg/m^2}$  and type 2 diabetes were at the highest risk for developing laryngeal cancer (HR: 2.02, 95% CI: 1.34-3.06).

Subgroup analyses were performed to determine whether the association between laryngeal cancer and underweight with type 2 diabetes varies according to participant characteristics (Fig. 3). The associations differed by age group (p for interaction, 0.01) and alcohol consumption (p for interaction, 0.004). Although the association between underweight, type 2 diabetes and laryngeal cancer remained significant in most subgroups, this association was more pronounced in subjects aged < 65 years (HR: 3.33, 95% CI: 1.88-5.87) and in those who were alcohol consumers (HR: 2.72, 95% CI: 1.64-4.53). Regarding the status of both underweight and type 2 diabetes, the HR (3.06, 95% CI; 1.67– 5.58) of laryngeal cancer was increased in subjects with anemia, although the with and without anemia groups might not be significantly different (p for interaction, 0.34).

### Discussion

To the best of our knowledge, this is the first nationwide population-based study on the relationship between underweight, type 2 diabetes and laryngeal cancer. Our results showed that underweight was associated with increased risk of laryngeal cancer, and this risk was stronger for those with type 2 diabetes. Thus, the combination of underweight and type 2 diabetes might result in a synergistic effect on the development of laryngeal cancer.

Traditionally, smoking and some environmental factors have been suggested as risk factors for HNC. The wellknown risk factors for laryngeal cancer include cigarette smoking and alcohol consumption, exposure to asbestos, polycyclic aromatic hydrocarbons (PAHs), and textile dust and dietary factors [26, 27]. Laryngopharyngeal reflux and human papilloma virus infection have also been suggested as possible risk factors [26-29]. Smoking has been shown to have a linear association with the development of laryngeal cancer, with a risk for smokers that is 10 to 15 times higher than the risk for nonsmokers [26]. It has been reported that the levels of DNA adduct formation by tobacco-specific nitrosamines (TSNA) and PAHs in smokers who have developed HNC are significantly higher [30, 31]. Since these aromatic DNA adducts are lipophilic, they can be distributed to adipose tissue [12]. Hence, low serum carcinogen levels can be found in patients with relatively high BMI [32]. This might explain

Table 3 Hazard ratios for developing laryngeal cancer, according to the status of underweight and type 2 diabetes


	IR (per 1000 person-years)	HR (95% CI)		
		Model 1	Model 2	Model 3
BMI, kg/m <sup>2</sup>				
Type 2 diabetes (–)				
< 18.5	0.046	1.31 (1.09-1.57)	1.19 (0.99–1.42)	1.20 (1.00-1.44)
18.5-22.9	0.040	1 (Reference)	1 (Reference)	1 (Reference)
23-24.9	0.039	0.80 (0.73-0.88)	0.86 (0.78-0.94)	0.85 (0.77-0.93)
25-29.9	0.035	0.72 (0.65-0.79)	0.79 (0.72-0.86)	0.76 (0.69-0.84)
≥30	0.019	0.66 (0.49-0.88)	0.72 (0.53-0.96)	0.67 (0.50-0.90)
BMI, kg/m <sup>2</sup>				
Type 2 diabetes (+)				
< 18.5	0.275	2.37 (1.57-3.58)	2.09 (1.38–3.15)	2.02 (1.34-3.06)
18.5-22.9	0.135	1.29 (1.11–1.48)	1.26 (1.09–1.45)	1.20 (1.04–1.39)
23-24.9	0.104	1.02 (0.87-1.19)	1.07 (0.91–1.25)	1.00 (0.85-1.17)
25-29.9	0.071	0.81 (0.70-0.94)	0.87 (0.75-1.01)	0.80 (0.69-0.94)
≥ 30	0.058	1.16 (0.81-1.68)	1.25 (0.87-1.81)	1.13 (0.78-1.64)

Model 1 was adjusted for age, sex

Model 2 was adjusted for age, sex, income status, smoking, alcohol consumption, and physical activity

Model 3 was adjusted for age, sex, income status, smoking, alcohol consumption, physical activity, type 2 diabetes, hypertension, dyslipidemia, and anemia *Abbreviations BMI* Body mass index, *CI* Confidence interval, *HR* Hazard ratio, *IR* Incidence rate (1000 person-year)

Lee et al. BMC Cancer (2022) 22:345 Page 7 of 10



**Fig. 3** Forest plots including subgroup analyses for the association between participant characteristics and laryngeal cancer. Subgroup analyses were performed to investigate the associations between age, sex, smoking, alcohol consumption, and anemia and the development of laryngeal cancer according to the status of underweight and type 2 diabetes. The analysis was adjusted for age, sex, income, smoking, alcohol consumption, regular physical activity, hypertension, dyslipidemia, and anemia

why the risk of the development of laryngeal cancer is higher in underweight individuals.

In addition, there are several other hypotheses as to why the risk of HNC is relatively high in the group with low BMI. First, painful premalignant lesions could result in dysphagia, odynophagia, and taste and appetite changes, and thus, a decrease in caloric intake may cause weight loss [12, 13]. Another possibility is that

Lee et al. BMC Cancer (2022) 22:345 Page 8 of 10

underweight patients may have relatively low vitamin and micronutrient levels, which may increase the risk of HNC [13, 31]. In patients showing chronic undernutrition and micronutrient deficiency, cytokine reactions and the subsequent activation of the immune system are compromised, which may affect tumor-immune system interactions [33]. Third, low socioeconomic status, especially low educational attainment, low income and undernutrition, has been reported as a potential risk for HNC [13, 34]. In the present study, undernutrition and socioeconomic status were adjusted by controlling for the presence of anemia and income status, respectively. Although the status of vitamins and micronutrients was not clinically measured, our results might confirm that underweight was associated with increased risk of laryngeal cancer after adjusting for potential confounders.

Diabetes mellitus (DM) is one of the most common diseases worldwide. There are approximately 5.34 million diabetic patients among the 50 million people in Korea [35].  $90 \sim 95\%$  of DM patients have type 2 disease that is characterized by years of insulin resistance and hyperinsulinemia preceding the development of hyperglycemia [36]. In particular, type 2 diabetes is a risk factor for cancer, particularly stomach, hepatocellular, hepatobiliary, pancreas, breast, ovarian, endometrial, kidney and colorectal cancers [7, 37, 38]. The possible connection between type 2 diabetes and cancer comprises hyperinsulinemia, hyperglycemia and fat-induced chronic inflammation [39]. High insulin levels inversely correlate with insulin-like growth factor binding protein (IGFBP)-1 and –2 levels, which potentially leads to more free IGF-1 at the tissue and cellular levels. Binding of insulin to the insulin receptor primarily activates the phosphoinositide 3-kinase (PI3K)– tyrosine kinase B (Akt)-mammalian target of rapamycin (mTOR) signaling pathway [36]. Binding of IGF-1 and IGF-2 to IGF-1R stimulates the PI3K-Akt-mTOR and Ras-Raf-MAPK pathways [36, 40]. These pathways may lead to mitogenic signaling and increased tumor growth or progression. One study reported that overexpression of IGF1R-alpha protein could act as an independent predictor of relapse and survival in operable laryngeal cancer patients [41]. A recent meta-analysis indicated that type 2 diabetes is associated with an increased risk of HNC in East Asia and that the risk of oral cancer was most significantly increased among HNC patients [42]. However, conflicting results have been reported on whether type 2 diabetes is associated with increased risk of laryngeal cancer [28, 42, 43]. On the other hand, BMI has a strong relationship with type 2 diabetes. Lean patients with type 2 diabetes may have a tendency toward certain pathophysiological characteristics, notably less insulin resistance and poorer insulin secretory capacity. They would have β-cell dysfunction, which might be more marked than that seen in overweight patients [44]. Since some lean patients with type 2 diabetes may be more insulin sensitive, PI3K-Akt-mTOR pathway could be further stimulated by insulin and IGF-1, compared to in obese patients. Accordingly, underweight and type 2 diabetes were shown to be synergistically associated with increased risk of newly developed laryngeal cancer after adjusting for confounders including smoking, in this study.

We found that alcohol consumers who were underweight and had type 2 diabetes were more likely to develop laryngeal cancer than those who did not consume alcohol. Generally, alcohol consumption has been known to be associated with an approximately 2-fold increase in risk of laryngeal cancer [45]. The direct association between alcohol consumption and HNC risk has been extensively described and potential mechanisms have been proposed [46]. Ethanol is oxidized to alcohol acetaldehyde, which is a recognized carcinogen. Furthermore, nutritional deficiencies may occur in individuals with alcoholism. Alcohol exposure may also have a synergistic effect with other carcinogens. Alcohol consumption may be responsible for strengthening the relationship between underweight in the presence of type 2 diabetes and laryngeal cancer. Further studies are needed to determine whether serum levels of carcinogens are actually high in underweight alcoholic patients.

It is unclear why the group under 65 years showed a stronger relationship between underweight, type 2 diabetes and laryngeal cancer. Long-term exposure to smoking and alcohol consumption is well known as a major risk factor for aerodigestive malignancies, including laryngeal cancer. It may be a lower attributable fraction for smoking and drinking in the group under 65 years compared to the group above 65 years. It is likely explained by some molecular- or genetic-level abnormalities. Dysregulation of the Akt pathway occurred in nonsmoker HNC patients, but did not occur in all of the smokers studied [47]. As mentioned above, the PI3K-Akt-mTOR pathway is very important for carcinogenesis associated with IGF-1. Further studies are needed to confirm whether this same signaling pathway supports the results of subgroup analysis of younger patients. In addition, based on the results of this study, more observation and education on laryngeal cancer prevention programs are needed in adults under the age of 65 years who are underweight and have type 2 diabetes. They also might need to undergo appropriate laryngeal cancer screenings to promote primary prevention and early detection.

There are some limitations in this study. First, we used an observational design; therefore, inferences of causality should not be made regarding the association of underweight and type 2 diabetes with the development Lee et al. BMC Cancer (2022) 22:345 Page 9 of 10

of laryngeal cancer. Second, we had limited information to define a pathologic classification of tumor and tumor stage. Third, our cohort comprised primarily Korean participants, and our results need to be validated in a more diverse population of patients. Fourth, the value of BMI was collected one time at health check-ups. Since BMI is a changeable variable, it may be different when laryngeal cancer is diagnosed. Finally, we could not directly assess the severity of type 2 diabetes or glycemic control status and did not have reliable information on the diverse combinations of medications used.

Despite these limitations, this is a nationally representative, population-based long-term cohort study evaluating the association of underweight and type 2 diabetes as risk factors for laryngeal cancer. A future study could help elucidate these two risk factors for laryngeal cancer outcomes.

#### **Conclusions**

We found that underweight was an independent risk factor for developing laryngeal cancer in a nationwide Korean general population-based cohort study. This study showed that underweight and type 2 diabetes were synergistically associated with a higher risk of laryngeal cancer. The risk of laryngeal cancer was stronger for those younger than 65 years old and alcohol consumers. Based on the results of this study, it might be necessary to more actively screen for laryngeal cancer in adults with underweight and type 2 diabetes, and clinical attention should be given to smoking cessation and to the elimination of environmental risk factors in this high-risk group.

#### Abbreviations

Akt: Tyrosine kinase B; BMI: Body mass index; CI: Confidence interval; CKD: Chronic kidney disease; DBP: Diastolic blood pressure; DM: Diabetes mellitus; DNA: Deoxyribonucleic acid; eGFR: Estimated glomerular filtration rate; HDL-C: High-density lipoprotein cholesterol; HNC: Head and neck cancer; HR: Hazard ratio; ICD-10: International Classification of Diseases, 10th version; IGF-1: Insulin-like growth factor 1; IGF1R: Insulin like growth factor 1 receptor; IGFBP: Insulin like growth factor binding protein; IR: Incidental rate; IRB: Institutional Review Board; KHIDI: Korea Health Industry Development Institute; MAPK: Mitogen activated protein kinase; MDRD: Modification of diet in renal disease; mTOR: Mammalian target of rapamycin; NHIS: National Health Insurance Service; PAH: Polycyclic aromatic hydrocarbons; P13K: Phosphoinositide 3-kinase; SBP: Systolic blood pressure; TSNA: Tobacco-specific nitrosamines; WC: Waist circumference; WHO: World Health Organization.

# Acknowledgements

This study was performed using the database from the National Health Insurance System (NHIS-2019-127) and the results do not necessarily represent the opinion of the National Health Insurance Corporation.

#### Authors' contributions

JHC and KDH had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors reviewed the manuscript and approved it for publication. Specific contributions include; Study concept and design: KDH, SHC, JHC. Acquisition, analysis, or interpretation of data: KDH, KNL, YMP, SHK, JHC. Drafting of the manuscript: OHL, JHC, SHK. Critical revision of the manuscript: YMP, SHK, YJK.

Statistical analysis: KDH, KNL. Obtained funding: SHK. Study supervision: YMP, SHK. The author(s) read and approved the final manuscript.

#### **Funding**

This research was supported by a grant (HI18C0275) of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea. The Ministry of Health & Welfare had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data.

#### Availability of data and materials

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

#### **Declarations**

#### Ethics approval and consent to participate

Our study was approved by the institutional review board (IRB) of the Catholic University of Korea (IRB No. VC21ZISI0191) and obtained permission from the National Health Insurance System (NHIS) to use the health checkup data. Informed consent for using this health information was exempted by the IRB. The study was conducted in compliance with the Declaration of Helsinki.

#### Consent for publication

Not applicable.

#### Competing interests

All authors declare no potential conflicts of interest.

#### **Author details**

<sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon-si, Republic of Korea. <sup>2</sup>Department of Epidemiology, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA. <sup>3</sup>Division of Endocrinology & Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. <sup>4</sup>Department of Biostatistics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. <sup>5</sup>Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea.

# Received: 3 November 2021 Accepted: 7 March 2022 Published online: 29 March 2022

# References

- National Health Statistics 2019. Korea National Health and Nutrition Examination Survey (KNHANES). 2020. Available from: https://knhanes. kdca.go.kr/knhanes/sub01/sub01\_05.do. [cited 2 Nov 2021]
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
- Jung KW, Won YJ, Hong S, Kong HJ, Lee ES. Prediction of Cancer incidence and mortality in Korea, 2020. Cancer Res Treat. 2020;52(2):351–8.
- Deng Y, Wang M, Zhou L, Zheng Y, Li N, Tian T, et al. Global burden of larynx cancer, 1990-2017: estimates from the global burden of disease 2017 study. Aging (Albany NY). 2020;12(3):2545–83.
- Kim SY, Han KD, Joo YH. Metabolic syndrome and incidence of laryngeal Cancer: a Nationwide cohort study. Sci Rep. 2019;9(1):667.
- Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402–11.
- Suh S, Kim KW. Diabetes and Cancer: Cancer should be screened in routine diabetes assessment. Diabetes Metab J. 2019;43(6):733–43.
- Wang J, Yang DL, Chen ZZ, Gou BF. Associations of body mass index with cancer incidence among populations, genders, and menopausal status: a systematic review and meta-analysis. Cancer Epidemiol. 2016;42:1–8.

Lee et al. BMC Cancer (2022) 22:345 Page 10 of 10

- Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78.
- Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of Cancer and Cancer-related mortality. Physiol Rev. 2015;95(3):727–48.
- Bhaskaran K, Douglas I, Forbes H, dos Santos Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014;384(9945):755–65.
- Radoï L, Paget-Bailly S, Cyr D, Papadopoulos A, Guida F, Tarnaud C, et al. Body mass index, body mass change, and risk of oral cavity cancer: results of a large population-based case-control study, the ICARE study. Cancer Causes Control. 2013;24(7):1437–48.
- Chen Y, Lee YA, Li S, Li Q, Chen CJ, Hsu WL, et al. Body mass index and the risk of head and neck cancer in the Chinese population. Cancer Epidemiol. 2019;60:208–15.
- Lubin JH, Gaudet MM, Olshan AF, Kelsey K, Boffetta P, Brennan P, et al. Body mass index, cigarette smoking, and alcohol consumption and cancers of the oral cavity, pharynx, and larynx: modeling odds ratios in pooled case-control data. Am J Epidemiol. 2010;171(12):1250–61.
- Franceschi S, Dal Maso L, Levi F, Conti E, Talamini R, La Vecchia C. Leanness as early marker of cancer of the oral cavity and pharynx. Ann Oncol. 2001;12(3):331–6.
- Maasland DH, van den Brandt PA, Kremer B, Schouten LJ. Body mass index and risk of subtypes of head-neck cancer: the Netherlands cohort study. Sci Rep. 2015;5:17744.
- Ramos-Garcia P, Roca-Rodriguez MDM, Aguilar-Diosdado M, Gonzalez-Moles MA. Diabetes mellitus and oral cancer/oral potentially malignant disorders: a systematic review and meta-analysis. Oral Dis. 2021;27(3):404–21.
- Peng YS, Lin JR, Cheng BH, Ho C, Lin YH, Shen CH, et al. Incidence and relative risk for developing cancers in women with gestational diabetes mellitus: a nationwide cohort study in Taiwan. BMJ Open. 2019;9(2):e024583
- Jung CH, Son JW, Kang S, Kim WJ, Kim HS, Kim HS, et al. Diabetes fact sheets in Korea, 2020: an appraisal of current status. Diabetes Metab J. 2021;45(1):1–10.
- Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12(10):e1001885.
- Park S, Chun J, Han KD, Soh H, Kang EA, Lee HJ, et al. Dose-response relationship between cigarette smoking and risk of ulcerative colitis: a nationwide population-based study. J Gastroenterol. 2019;54(10):881–90.
- 22. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia. 2000. Available from: http://iris.wpro.who.int/handle/10665.1/5379. [cited 2 Nov 2021]
- 23. Ko SH, Han K, Lee YH, Noh J, Park CY, Kim DJ, et al. Past and current status of adult type 2 diabetes mellitus Management in Korea: a National Health Insurance Service database analysis. Diabetes Metab J. 2018;42(2):93–100.
- 24. Lamb EJ, Tomson CR, Roderick PJ. Estimating kidney function in adults using formulae. Ann Clin Biochem. 2005;42(Pt 5):321–45.
- Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. World Health Organization. 2011. Available from: https://apps.who.int/iris/handle/10665/85839. [cited 2 Nov 2021]
- Steuer CE, El-Deiry M, Parks JR, Higgins KA, Saba NF. An update on larynx cancer. CA Cancer J Clin. 2017;67(1):31–50.
- Cattaruzza MS, Maisonneuve P, Boyle P. Epidemiology of laryngeal cancer. Eur J Cancer B Oral Oncol. 1996;32b(5):293–305.
- Menicagli R, Bolla G, Menicagli L, Esseridou A. The possible role of diabetes in the etiology of laryngeal Cancer. Gulf J Oncolog. 2017;1(23):44–51.
- 29. Jurkiewicz D, Dzaman K, Rapiejko P. Laryngeal cancer risk factors. Pol Merkur Lekarski. 2006;21(121):94–8.
- 30. Jethwa AR, Khariwala SS. Tobacco-related carcinogenesis in head and neck cancer. Cancer Metastasis Rev. 2017;36(3):411–23.
- Kumar M, Nanavati R, Modi TG, Dobariya C. Oral cancer: etiology and risk factors: a review. J Cancer Res Ther. 2016;12(2):458–63.
- Godschalk RW, Feldker DE, Borm PJ, Wouters EF, van Schooten FJ. Body mass index modulates aromatic DNA adduct levels and their persistence in smokers. Cancer Epidemiol Biomark Prev. 2002;11(8):790–3.
- Cunningham-Rundles S, McNeeley DF, Moon A. Mechanisms of nutrient modulation of the immune response. J Allergy Clin Immunol. 2005;115(6):1119–28 quiz 29.

- Conway DI, Purkayastha M, Chestnutt IG. The changing epidemiology of oral cancer: definitions, trends, and risk factors. Br Dent J. 2018;225(9):867–73.
- 35. Kim YJ, Park SY, Oh KW. Diabetes prevalence and Management in Korean Adults. Seoul: Korea National Health and Nutrition Examination Survey (KNHANES); 2021.
- 36. Shlomai G, Neel B, LeRoith D, Gallagher EJ. Type 2 diabetes mellitus and Cancer: the role of pharmacotherapy. J Clin Oncol. 2016;34(35):4261–9.
- 37. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:q7607.
- Kim SK, Jang JY, Kim DL, Rhyu YA, Lee SE, Ko SH, et al. Site-specific cancer risk in patients with type 2 diabetes: a nationwide population-based cohort study in Korea. Korean J Intern Med. 2020;35(3):641–51.
- Wojciechowska J, Krajewski W, Bolanowski M, Kręcicki T, Zatoński T. Diabetes and Cancer: a review of current knowledge. Exp Clin Endocrinol Diabetes. 2016;124(5):263–75.
- Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism. 2019;92:121–35.
- Mountzios G, Kostopoulos I, Kotoula V, Sfakianaki I, Fountzilas E, Markou K, et al. Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer. PLoS One. 2013;8(1):e54048.
- 42. Yan P, Wang Y, Yu X, Liu Y, Zhang ZJ. Type 2 diabetes mellitus and risk of head and neck cancer subtypes: a systematic review and meta-analysis of observational studies. Acta Diabetol. 2021;58(5):549–65.
- 43. Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA. Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer. 2011;128(3):635–43.
- 44. Brunetti P. The lean patient with type 2 diabetes: characteristics and therapy challenge. Int J Clin Pract Suppl. 2007;153:3–9.
- Islami F, Tramacere I, Rota M, Bagnardi V, Fedirko V, Scotti L, et al. Alcohol drinking and laryngeal cancer: overall and dose-risk relation—a systematic review and meta-analysis. Oral Oncol. 2010;46(11):802–10.
- Di Credico G, Polesel J, Dal Maso L, Pauli F, Torelli N, Luce D, et al. Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration. Br J Cancer. 2020;123(9):1456–63.
- Toner M, O'Regan EM. Head and neck squamous cell carcinoma in the young: a spectrum or a distinct group? Part 2. Head Neck Pathol. 2009;3(3):249–51.

# **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.